Delivering Pharma Value: Where Is the Optimal Home for Health Economics and Outcomes Research (HEOR)?

Speakers

Betsy J Lahue, MPH, Alkemi, Manchester Center, VT, United States; Shuvayu Sen, PhD, Merck & Co., Rahway, NJ, United States

Pharmaceutical companies often restructure HEOR functions for strategic impact, but where does HEOR truly belong? Competing models include alignment with Market Access for value-driven commercial outcomes and alignment with Medical for comprehensive evidence generation and influencing the overall drug development program. Join industry experts and weigh in on this debate: Which structure provides the best “home” for HEOR professionals to shape impactful strategies and deliver desired outcomes for healthcare stakeholders?

Code

089

Topic

Economic Evaluation, Health Technology Assessment, Organizational Practices

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×